Bullish IBRX thesis citing a chairman tweet, positive lung cancer trial results, Saudi biotech summit cash potential, and a heavily shorted small float creating squeeze conditions.
IBRX — LONG The author argues ImmunityBio is a prime squeeze candidate because free float is only ~89M shares while short interest is 121M, meaning 136% of the float is shorted. Positive ANKTIVA lung cancer data and the chairman's tweet suggest upcoming good news, and the company's presence at the US-Saudi Biotech alliance summit could yield upfront cash. The author frames this as a potential 'baby GME' or DRUG-style squeeze, with the main risk being that the anticipated news or cash does not materialize.
136% of the float is shorted and shares are slowly being scooped up on a steady incline (up 33% this week). I hate to say this but this could be a baby $GME or give us another $DRUG.
This Reddit post, published January 14, 2026, features u/Due-Papaya-6217 discussing IBRX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Due-Papaya-6217 · Tickers: IBRX